Biotechnology
AbbVie's Correction Appears to Be Over: Here's Where the Stock Could Be Headed
Should you be a buyer?
I'm Still Expecting a Bear Market Bounce, So Here's What I'm Stalking
For all the sound and fury surrounding Snap's bad news, it really didn't change much when it comes to the broader market.
Bottom Fishing for Biotech Bargains
Here are three names I have added to in May.
A 'Mag'nificent Way to Play an AdTech Rebound
Similar to biotech, the small adtech space has been hammered in recent quarters and has likely hit oversold territory.
As the Market Struggles to Bounce Back, Here's My Game Plan
Many stocks are very oversold, and sentiment is about as bad as it gets.
2 Biotech Stocks to Own as M&A Potentially Gathers Steam
I like these names as stand-alone entities but they should also attract interest from larger players.
If You Insist on Trading This Brutal Market, Don't Get Lazy With Your Stops
That word of warning applies to ETFs and individual stocks such as Intercept Pharmaceuticals, which we outline a trading strategy for here.
Let's Pick Through the Carnage in the Biotech Sector for Ways to Play It
An ETF provides one opportunity, as do a few individual stocks.
What Kind of Treatment Should We Give Regeneron Shares After Earnings?
The biotech company tests a key indicator, and here's how investors should proceed, according to the technical readout.
Has Regeneron Pharmaceuticals Run Too Far?
Traders have one of two choices to make here.